Kornimate/medical-research-clean huggingface dataset:
relapse prevention and changing habits in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: this study aims to optimize a treatment package for the relapse prevention treatment of an. in the preparation phase, we examined accessibility and feasibility of the treatment package. in the current optimization phase, we will identify which components of treatment contribute to positive outcomes after acute hospitalization. we will carefully evaluate maintenance of remission, measured by rate of weight loss and end-of-trial status.

while many approaches to reducing relapse after hospital care have been tried, there is little information about which treatment elements confer benefit. this trial, relapse prevention and changing habits (reach+), targets the habitual control of maladaptive behavior to support patients with an in the 6 months after acute treatment, a time of high vulnerability to relapse. each component of reach+ addresses a question that is critical to answer in order to identify and optimize a relapse prevention treatment package that balances efficacy and burden. we will test the acceptability and feasibility of 5 components that together target habits: 1) behavioral, 2) cognitive, 3)motivation, 4) food monitoring, and 5) skill consolidation. in the preparation phase, 10 participants were enrolled, and accessibility and feasibility of the treatment package was examined. the current optimization phase includes a finalized treatment manual (including an online platform) and will test each component's contribution to weight maintenance after acute treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of anorexia nervosa at hospital admission * medically stable * internet capability with videoconferencing * weight restored (bmi \> 19 kg/m2) at new york state psychiatric institute exclusion criteria: * current substance use or other comorbid disorder requiring specialized treatment * pregnancy * imminent risk of suicide * serious medical illness * daily psychotropic medication other than antidepressants (medications that are known effect weight are exclusionary, i.e. stimulants, olanzapine, mirtazapine) * participation in outside psychotherapy or structured treatment program (support groups will be allowed). individuals who are discharged on medications would need to have a non-study psychiatrist.
safe and timely antithrombotic removal (star) registry

Conditions: Hemorrhage, Surgical; Hemorrhage Postoperative; Blood Loss, Surgical; Blood Loss, Postoperative

Summary: this registry will capture real-world clinical use patterns and associated clinical outcomes with the use of cytosorb for the removal of antithrombotic agents.

the star registry will collect patient-level clinical data on antithrombotic removal with cytosorb. the decision to use cytosorb in this clinical setting is based on the clinical rationale of mitigating the high risk of bleeding events that is directly linked to the presence of the antithrombotic agent. this registry is to capture real-world clinical use patterns and associated clinical outcomes with the use of cytosorb. data of retrospective and prospective patients will be included in the registry. safety will be assessed by collection of (at least possibly) device-related adverse events. data collection is done up to 30 days post-operation.

Eligibility criteria:
inclusion criteria: * cytosorb utilization for antithrombotic removal * informed consent for prospective registry participation exclusion criteria: • use of cytosorb for purpose other than antithrombotic removal
pet ownership and glucose control in type 1 diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: the investigators' long-term goal is to discover novel, inexpensive and feasible strategies to improve the management and well-being of youth with t1dm. the specific objective of this proposal is to quantify the impact of responsible pet ownership on the glycemic control and health related quality of life in youth with t1dm.

type 1 diabetes mellitus (t1dm) affects 151,000 children and adolescents in the united states. youth with t1dm are at a high risk for multiple psychosocial co-morbidities including poor health related quality of life (hrqol) which is linked to medication non-compliance and increased risk for diabetes-related complications. any reduction in the psychosocial adjustment difficulties related to t1dm could improve the medical outcome of children with t1dm. current standards for diabetes management reflect the need to maintain glucose control within a normal range. however, numerous reports indicate that normalization of blood glucose levels is seldom attainable in children and adolescents. family cohesion, positive coping strategies, younger age of onset, social support and adequate self-regulatory behavior are found to favorably influence glycemic control. one may conclude that the presence of a companion animal, capable of enhancing the positive factors named above, would augment the array of tools available for the successful management of chronic illnesses such as t1dm. there is a lack of studies assessing the impact of pet ownership on the health and well-being of adolescents. the process of caring for, loving and being loved by a companion animal could offer direct and/or indirect benefits to the hrqol in children with t1dm. to the investigators' knowledge, there are no studies examining the impact of pet ownership on glycemic control and hrqol in youth with t1dm.

Eligibility criteria:
inclusion criteria: * english-speaking patients * 10 to 18 years * diagnosed with type 1 diabetes for at least 12 months * poor diabetes control as defined by having a hemoglobin a1c value \> 8% exclusion criteria: * type 2 diabetes * developmental delay * current participation in another study that may impact glycemic control

Keywords: adolescence self care
fmt for steroid resistant gut acute gvhd

Conditions: Stem Cell Transplant Complications; Acute Graft-Versus-Host Disease; Fecal Microbiota Transplantation

Summary: the study aims to evaluate the safety and efficacy of fecal microbiota transplantation (fmt) for the treatment of steroid resistant graft-versus-host-disease (gvhd) of the gut. this strategy might offer a safe and effective therapeutic approach for these patients with a poor prognosis and limited therapeutic options.

graft-versus-host-disease (gvhd) is a major complication after hematopoietic stem cell transplantation (hsct). gut is the most vulnerable target organ of acute gvhd. patients who develope the acute gut gvhd and do not respond to the first line therapy with steroids have a high mortality. the investigation of safe and effective second line therapy for these patients are in need. the study evaluates safety and efficacy of fecal microbiota transplantation (fmt) for the treatment of streoid resistant gvhd of the gut. stool for fmt will be prepared from the healthy donor.this strategy might offer a safe and effective therapeutic approach for these acute steroid resistant gut gvhd patients.

Eligibility criteria:
inclusion criteria: * 1. adults(ages are elder than 18 years and younger than 75 years) who developed gut acute graft-versus-host disease(agvhd) after allogeneic hematopoietic stem cell transplantation(hsct) and were resistant to a first line therapy with steroids. 2. patients who were diagnosed as stage 3 or 4 gastro-intestinal acute graft-versus-host(gi-agvhd) with the symptoms such as diarrhea or abdominal pain. 3. participants who accepted the fmt treatment. 4. signature of informed and written consent by the subject. exclusion criteria: * 1. patients who were diagnosed as stage 1 or 2 gastro-intestinal acute graft-versus-host(gi-agvhd) 2. patients with unstable vital signs or severe cardiac and pulmonary disorder. 3. patients who were failure to cooperate endoscopy examination. 4. patients who were younger than 18 years or pregnant. 5. patients who were poor compliance to fmt treatment. 6. patients who were not able to give informed consent.
the risk of major bleeding with novel anti-platelets: a comparison of ticagrelor with clopidogrel in a real world population of 5000 patients treated for acute coronary syndrome

Conditions: Acute Coronary Syndrome; Bleeding; Novel Anti-platelets; Ticagrelor; Clopidogrel

Summary: a retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in acs patients.

major bleeding after myocardial infarction portends a poor outcome. a balance is required between potency of platelet inhibition and risk of bleeding. ticagrelor provides faster and more effective platelet inhibition than clopidogrel. in the plato trial ticagrelor reduced the incidence of cardiovascular death, myocardial infarction and stroke compared to clopidogrel after acs (acute coronary syndrome). although there was no difference in overall bleeding there was more non-cabg related major bleeding with ticagrelor. it has since been recommended, in addition to aspirin, in treatment of moderate-high risk acs by both esc (european society of cardiology) and nice (national institute for clinical excellence). there has been widespread adoption as first line therapy in uk hospitals. there remains potential concern about bleeding in a "real world" population compromising more high risk patients; particularly more elderly and female, than those in plato. the investigators intend to perform a large "real world" comparison of bleeding risk with ticagrelor compared to clopidogrel in a uk acs population. the investigators plan an observational cohort study of patients presenting with acs at 5 district general hospitals in merseyside and cheshire. the investigators will collect data retrospectively on 2500 patients treated with clopidogrel prior to the guideline change and 2500 treated with ticagrelor thereafter. the primary end point will be incidence of barc 3-5 (bleeding academic research consortium) and plato major bleeding.

Eligibility criteria:
inclusion criteria: 1. patient commenced on clopidogrel for acs prior to change of acs guidelines, or tiacgrelor for same indication afterwards. exclusion criteria: 1. patient already taking the drug in question (clopidogrel or ticagrelor) prior to the acs event 2. patients under 18 years of age 3. patients in whom the drug is stopped during the same hospital admission due to clinical judgement dictating that it is no longer indicated (this does not apply to patients in whom a bleeding event is the precipitant for stopping the drug)
utilizing 3d printed personalized aortic lesion models in preoperative assessment

Conditions: Aortic Aneurysm

Summary: using 3d printing technology to create personalized models of diseased heart and aortic blood vessels, surgeons can perform preoperative planning and evaluate relevant indicators.

background： previous systematic reviews have indicated that approximately 82% of surgeries using 3d printed lesion models for preoperative planning have shown better surgical outcomes, and about half of the surgeries have demonstrated reduced operative time. in recent years, there have been numerous studies focusing on the application of 3d printing technology in aortic aneurysms. this study aims to employ 3d printing technology to fabricate personalized aortic blood vessel models with lesions. study design： a single-centre, pilot study. methods： this study is a single-center, prospective clinical trial. the study plans to enroll 10 participants in the experimental group, and collect data from another 10 participants as the historical control group. the historical control group data will be matched-paired based on gender, age, and surgical type in sequential order. effect： we anticipate that through the use of 3d printed lesion models, we can reduce surgical time, decrease surgery-related complications, and enhance the smoothness of surgical team preparation for the procedure. additionally, this approach can provide patients with a better understanding of their own condition and the upcoming surgical intervention. key words： 3d printing; pre-operative planning; thoracic aorta aneurysm; abdominal aorta aneurysm

Eligibility criteria:
inclusion criteria: * diagnosed with thoracic or abdominal aortic aneurysm * signed surgical consent * non-emergent surgery * had 2d ct imaging within the last 6 months exclusion criteria: * refusal to use lesion images for model creation * refusal to participate in the study

Keywords: 3d printing pre-operative planning thoracic aorta aneurysm abdominal aorta aneurysm
treatment of angiotensin peptide (1-7) for covid-19

Conditions: COVID-19

Summary: novel coronavirus is reported to cause covid-19, recently. it's known that this virus uses ace (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ace 2. upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in covid-19 cases, can be a result of angiotensin peptide (1-7) deficiency. therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of covid-19 cases.

novel coronavirus is reported to cause covid-19, recently. it's known that this virus uses ace (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ace 2. upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in covid-19 cases, can be a result of angiotensin peptide (1-7) deficiency. therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of covid-19 cases.

Eligibility criteria:
inclusion criteria: * accepted to participate with an informed consent * proven positive covid-19 exclusion criteria: * declined to participate * genetic/chromosomal abnormalities * any kind of history of previous adverse events with transfusion * diagnosis of immune deficiency
home outpatient monitoring and engagement to predict hf exacerbation

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: the home predict hf study looks at new ways to predict hospitalizations for heart failure. we will use a set of devices at home and surveys to collect information about patient's health. this study uses the eureka app, a new study app developed by the university of california, san francisco. the study is designed to happen remotely, using this application on a patient's smartphone, so that is as convenient as possible to participate.

home predict hf is single center, prospective, unblinded, randomly assigned training and validation observational cohorts to develop machine learning algorithms from an in-home suite of sensors in order to predict 3-month heart failure hospitalization and/or emergency department visits. study population includes adults presenting with a diagnosis of reduced ejection fraction (lvef \<= 40%), nyha class ii-iv) who have had a hospitalization for hf in the previous 6 months. the study objectives include (1) to collect observational data from multiple sensors, patient-reported outcomes, and medical record data to develop (train) machine-learning algorithms (2) to validate trained algorithms in a separate validation cohort (3) to collect data to inform the design of a future intervention study. the primary outcome is ninety-day heart failure hospitalization/emergency department visit for heart failure.

Eligibility criteria:
inclusion criteria: 1. outpatient and cared for by a pinnacle registry practice 2. age ≥ 18 years old 3. has a diagnosis of hf in the pinnacle registry/medical record 4. seen by pinnacle practice within the last 12 months 5. has an lvef ≤40% on their last data entry (within 1 year) in the pinnacle registry 6. nyha class ii-iv by self-report 7. has had a hospitalization for hf in the previous 6 months by self-report 8. owns an android or ios smartphone, within verizon cellular coverage zone in order to allow for data submission. 9. sleep in the same bed at least 5 days per week 10. willingness to complete the required surveys, measurements and study activities. exclusion criteria: 1. home oxygen use 2. current or planned ventricular assist device 3. previously or currently on a heart transplant list 4. chronic dialysis 5. a diagnosis of any cancer and undergoing active treatment 6. in hospice or palliative care 7. planned surgery/procedure in the next 3 months 8. planned extended time away from home (\>2 weeks) in the next 3 months 9. living in a skilled nursing facility or other chronic care facility 10. pregnancy or planned pregnancy in the next 3 months 11. inability or unwillingness to consent and/or follow requirements of the study

Keywords: hospitalization
study of lung stereotactic adaptive ablative radiotherapy

Conditions: Lung Cancer; Lung Tumor

Summary: the proposed study expands on the principles of sbrt (stereotactic body radiation therapy) and sabr (stereotactic ablative radiotherapy) for centrally located nsclc (non-small cell lung cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age * clinical diagnosis of nsclc * stage t1-2b (≤ 5 cm) exclusion criteria: * prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (i.e., carcinomas in situ of the breast, oral cavity, or cervix are permissible); previous lung cancer, if the patient is disease-free for a minimum of 1 year is permitted; * prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * prior chemotherapy for the study cancer * plans for the patient to receive other local therapy (including standard fractionated radiotherapy and/or surgery) while on this study, except at disease progression * plans for the patient to receive systemic therapy (including standard chemotherapy or biologic targeted agents), while on this study, except at disease progression
characterization of transcriptional regulators of ghrelin hormone which causes genetic obesity

Conditions: Prader Willi Syndrome; Obesity

Summary: the problem point of the prader-willi syndrome (pws) patient is the obesity which is intense and the plasma ghrelin level which increases unusual from the recently pws patients was discovered. the ghrelin is endogeneous ligand of growth hormone secretagogue receptor with peptide hormone and the location is 3p26-p25. becomes the secretion even from nervous system but from dignity x/a cell it is secreted mainly and growth is important even in the vagal control against food and intake and a dignity function even on the action outside which promotes the secretion which drives it operates. it increases food intake specially and in order to accomplish the action which diminishes fat utilization the obesity with the week cause which it does the mortar it is thought. active the ghrelin of the form is essential in hormonal activity of the ghrelin and appetite and growth hormone it participates to the secretion promotion which drives. action of the ghrelin measuring the quantitative change in middle acylated of the pws patient ghrelin in order to happen after the acylation initially by one interest ghrelin which is attempted the appetite of the pws patient is is controlled the method it will be able to prove the thing directly, it used the ria kit and the elisa it will be able to measure kit it will be able to measure the whole ghrelin to pick the pws patient and the blood of the normal army and active ghrelin it measured a change.

it will reach to respect, in 5 ' -flanking region of the ghrelin 2000 bp focus it let and it got luciferase assay it led and and it searched for the binding it sorted it put out and and to sleep the transcription factor which and and is the possibility of doing the essential region in the transcription and and it did an order deletion clone and and. is important in result and ghrelin activity the region role, -300\~-200 region basic helix-loop-helix (bhlh) are containing -usf (-236 to -231) binding site specially to be compressed in -500\~-400 and -300\~-200 two portions.

Eligibility criteria:
inclusion criteria: * pws patients were genetically confirmed using the standard methylation test. ghd was diagnosed using a gh stimulation test. the lean and obese normal subjects (comparison group) enrolled were the children or siblings of hospital staff who understood the purpose of and the procedures used. exclusion criteria: * ghd patients had no history of gh treatment, and were not being treated with gh at study commencement
prevalence of glaucoma in belgium: a multicenter national trial

Conditions: Glaucoma

Summary: to screen for the presence of glaucoma in a belgian population over 40 years old using an ai algorithm developed for the detection of glaucoma based on fundus pictures.

in this study, we aim to detect individuals with glaucoma and refer them for further evaluation and treatment when necessary. in so doing, we want to get an estimation of the prevalence of glaucoma in the belgian population of 40+ years. a fundus picture will be acquired without pupil dilation. this examination will be followed by an intra-ocular pressure measurement. the results will be discussed with the participating subject by the present physician. for each subject, both eyes will be evaluated. in case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.

Eligibility criteria:
inclusion criteria: * aged 40 years or above exclusion criteria: * aged under 40 years * insufficient knowledge of dutch, french or english required to complete the imaging protocol and questionnaire * physical or mental inability to participate
a study to evaluate the safety and tolerability of sage-718 in participants with mild cognitive impairment or mild dementia due to alzheimer's disease (ad)

Conditions: Alzheimer Disease; Cognitive Dysfunction; Mild Dementia

Summary: the primary purpose of this study is to evaluate the safety and tolerability of sage-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (mci) or mild dementia due to alzheimer's disease (ad).


Eligibility criteria:
inclusion criteria: 1. participant meets the following criteria for mci or mild dementia due to ad at screening: has a memory complaint, has clinical dementia rating (cdr) score of 0.5 to 1.0 (inclusive) with a memory box score ≥0.5, has essentially preserved activities of daily living 2. participant has a score of 15 to 24 (inclusive) on the montreal cognitive assessment at screening 3. participant has normal premorbid intelligence quotient (iq) at screening 4. participant has a study partner who is reliable, competent, at least 18 years of age, willing to be available to the study center by phone, support study-specific activities, and accompany the participant to study visits as needed exclusion criteria: 1. participant has any medical or neurological condition (other than ad) that might be contributing to the participant's cognitive impairment or history of cognitive decline 2. participant has a history of brain surgery, deep brain stimulation, a significant head injury causing loss of consciousness greater than 30 minutes, or hospitalization due to a brain injury 3. participant has a history, presence, and/or current evidence of a clinically-significant intracranial abnormality (eg, stroke, hemorrhage, space-occupying lesion) that could account for the observed cognitive impairment (excluding abnormalities consistent with underlying ad pathology) 4. participant has a history of possible or probable cerebral amyloid angiopathy, according to the boston criteria 5. participant has a history of seizures or epilepsy, with the exception of a single episode of febrile seizures in childhood 6. participant has current or recent suicidality